Abstract:Background: Botulinum toxin (BTX) is an effective management method for spasticity in children with cerebral palsy (CP), but the short- medium- and long-term effects remain unclear. Objective: The primary objective was to quantify the effects of BTX injections on upper limb spasticity over time in children with CP. The secondary objective was to evaluate efficacy according to the International Classification of Functioning, Disability, and Health-Children & Youth version framework. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials that included control/comparison groups treated with a placebo or other treatments. We searched CINAHL, Embase, PubMed, Scopus, Web of Science, and PsycINFO from their inception to April 2024. The pooled mean difference (MD) or standard mean difference (SMD) with 95 % CI was calculated using a random effects model at the short-term (up to 3 months), medium-term (3 to 6 months), and long-term (over 6 months). Results: A total of 658 children with CP aged 1.8 to 19 years old in 12 eligible trials were involved. The primary outcome of the Melbourne Assessment percentile showed a significant increase in the medium- (MD = 2.63, 95 % CI 0.22 to 5.04, I² = 0 %) and long-term (MD = 4.72, 95 % CI 0.93 to 8.51, I² = 0 %) in favor of BTX. Pooled effects also showed that BTX significantly improved Modified Ashworth Scale scores in the short- (MD = -0.44, 95 % CI -0.88 to -0.01, I² = 88 %) and medium-term (MD = -0.20, 95 % CI -0.28 to -0.13, I² = 0 %), and individual goals and bimanual performance up to 6-months. No significantly higher risk of adverse events was observed with BTX. Conclusions and implications: BTX injections sustainably improved the quality of affected upper limb function and temporarily improved individual goals and bimanual performance in children with CP. Our findings cautiously support a time interval of 3 to 6 months between BTX injections in the upper limbs of children with CP. Trial registration: This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (Registration ID: CRD42022323672).

[Clinical experience of the repeated multilevel injections of the botulinum toxin type A (abobotulinum toxin A) in the spastic forms of cerebral palsy].

[Multilevel botulinum toxin treatment in severe spastic forms of cerebral palsy (GMFCS IV-V)]

[Selection of a dose of the botulinum toxin A in spastic forms of cerebral palsy]

Long-term effect of repeated injections of botulinum toxin in children with cerebral palsy: A prospective study

The Effect of Different Localizing Techniques in Guiding Botulinum Toxin Injection in the Treatment of Lower Limb Spasticity in Cerebral Palsy Children

Repeat injection of botulinum toxin A is safe and effective for upper limb movement and function in children with cerebral palsy

Effectiveness of Ultrasound-Guided Botulinum Toxin Injection Combined with Orthosis Training in the Treatment of Lower Limb Spasticity

Should botulinum toxin A injections be repeated in children with cerebral palsy? A systematic review

Efficacy of Repeated Botulinum Toxin Type A Injections for Spastic Equinus in Children with Cerebral Palsy—A Secondary Analysis of the Randomized Clinical Trial

High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy

Short- medium- and long-term effects of botulinum toxin on upper limb spasticity in children with cerebral palsy: A meta-analysis of randomized controlled trials

Efficacy and safety of serial injections of botulinum toxin A in children with spastic cerebral palsy

Clinical Efficacy of Multipoint Injection of Botulinum Toxin in the Treatment of Spastic Cerebral Palsy in Children

Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy

Over 25 Years of Pediatric Botulinum Toxin Treatments: What Have We Learned from Injection Techniques, Doses, Dilutions, and Recovery of Repeated Injections?

A prospective study investigating gross motor function of children with cerebral palsy and GMFCS level II after long-term Botulinum toxin type A use

BOTULINUM TOXIN IN THE MANAGEMENT OF THE LOWER LIMB IN CEREBRAL PALSY

Intrathecal Baclofen Infusion-Botulinum Toxin Combined Treatment Efficacy in the Management of Spasticity due to Cerebral Palsy

A Clinical Research on Local Intramuscular Injection of Botulinum Toxin A and Rehabilitation Training in the Treatment of Spastic Cerebral Palsy

IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial

Effects of botulinum toxin A on calf muscles in children with cerebral palsy: a systematic review